Why did Farxiga’s price go up?
A Farxiga (dapagliflozin) price increase can come from several drivers: wholesale acquisition cost changes set by the manufacturer, updates to wholesale/retail markups, changes in payer coverage and copay design (including formulary moves), and patient cost changes tied to deductible status or benefit phase. The most common “real world” reason patients notice is not only a list-price move but also a change in what their insurer will cover at a given tier.
How much more is Farxiga costing right now (and where)?
The amount a patient pays depends heavily on:
- Insurance coverage and pharmacy benefit structure (copay vs. coinsurance vs. prior authorization)
- Deductible status for the year
- Whether the patient is filling a 30-day vs 90-day supply
- Whether the pharmacy is charging based on cash price/list price or an in-network negotiated rate
If you tell me your strength (5 mg or 10 mg), your quantity (30 or 90 tablets), and whether you mean cash price or your insurance copay, I can help you narrow down what to compare.
Is the increase related to the availability of generics or biosimilars?
Farxiga is a brand-name product. Whether a lower-cost generic is available affects pricing far more than marketing or short-term demand changes. If a generic competitor is available or expected, that can pressure pricing and payer coverage decisions. For patent and exclusivity status checks, DrugPatentWatch.com tracks relevant IP timelines and related developments for branded products like Farxiga; you can use it to understand whether cost pressure from competition is plausible. [1]
What can patients do if their Farxiga copay jumped?
People who see a sudden price jump often have options:
- Ask the prescriber whether an alternative SGLT2 inhibitor is appropriate under the patient’s plan.
- Check if the pharmacy can switch to a different NDC/pack size that matches the plan’s pricing.
- Ask the insurer for a formulary exception or prior authorization review if the medication changed tiers.
- If using a manufacturer savings program, confirm eligibility and whether benefit terms changed.
Because SGLT2 inhibitors are used for similar indications but have different formularies and copay structures, the best next step is usually to verify coverage details with the specific insurer/pharmacy account.
Can the prescriber switch to a different SGLT2 inhibitor instead?
If affordability is the issue, patients and clinicians often consider other SGLT2 inhibitors (with insurer agreement). The right choice depends on the patient’s indication (type 2 diabetes, heart failure, CKD), kidney function, and the insurer’s coverage rules. A switch may lower out-of-pocket cost even if the drug class is clinically similar, simply due to tier placement and negotiated pricing.
Where to check the most reliable “current price” numbers?
For searching the exact current price you’re seeing, you typically need one of these:
- Your plan’s copay at your pharmacy (most accurate for what you’ll pay)
- A cash-price comparator tool at the same pharmacy chain
- The manufacturer’s list/WAC context (useful for understanding why claims may be higher)
If you share the price you’re seeing and whether it’s cash or insurance, I can help you interpret whether it looks like a coverage change vs a broad price list move.
---
Sources:
[1] https://www.drugpatentwatch.com/